HER2-Positive Gastrointestinal Cancers — Microlearning Activity 1: Proceedings from a Session Held Adjunct to the 2026 ASCO GI Cancers Symposium
Oncology Today with Dr Neil Love
00:00
Should targeted therapy replace frontline chemoimmunotherapy?
Discussion on sequencing: consider trials first; second‑line HER2 agents are approved but frontline data pending.
Play episode from 04:58
Transcript
